Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes
Authors' conclusion
Time to progression to stage 3 appeared similar between the TN-10 placebo arm and the Fr1da group and between participants with and without FDRs with disease. Results suggest progression risk from the TN-10 trial may be generalizable to European populations with or without FDRs with type 1 diabetes.
Study context
- Population
- Individuals with stage 2 T1D from the TN-10 placebo arm and the Fr1da population-based screening program in Germany
- Participants
- 32 vs 152
- Exposure
- TN-10 placebo arm vs Fr1da group
- TN-10 placebon = 32
- Fr1dan = 152reference
- Outcome
- Time to progression from stage 2 to stage 3 T1D
Methodological detailscomparison of TN-10 placebo arm with population-based screening cohort
- Comparison of TN-10 placebo arm with population-based screening cohort
Main finding
As reported in the abstract
Risk of progression to stage 3 T1D
TN-10 placebo vs Fr1daEstimate (95% CI)
Risk of progression to stage 3 T1D
HR 1.3(0.8–2.1)
Adjusted for anti-IA-2 antibodies, HbA1c >5.7%, and 120-min OGTT
adjusted HR 1.1(0.6–2.1)
Observational data: associations, not effects.
Further findings
Time to progression to stage 3 in Fr1da participants with vs without first-degree relatives (FDRs) with T1D
- Fr1da participants with (n = 45) and without (n = 107) FDRs with T1D had similar time to progression to stage 3
Age-based subanalysis
- Minimal impact of age on progression time
Original publication
Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes. Diabetes Care. Published 21 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →